Advertisement

Topics

Nextech Venture, L.P Company Profile

17:29 EDT 24th September 2018 | BioPortfolio

Nextech Venture, L.P., founded in 1999, is a U.S. limited partnership withCHF 70 million under management and with an office in Zurich, Switzerland. We are investing in selected life science companies in Europe.
We help build up successful business ventures from innovations originating in academia and industry in life science and we also support the incubation process of a strong research team in the process of identifying a market and developing the strategy to conquer it.

Location

Scheuchzerstrasse 35
Zurich
Schlieren
CH-8006
Switzerland

Contact

Phone: 41 (0)44 366 66 11
Fax: 41 (0)44 366 66 10
Email: info@nextechventure.com


News Articles [109 Associated News Articles listed on BioPortfolio]

IDEAYA closes $94mm Series B round

Oncology firm IDEAYA Biosciences Inc. raised $94mm through a crossover Series B round co-led by Nextech Invest, 6 Dimensions Capital, and Perceptive Advisors. Additional new investors BVF Partners, GV...

Nextech leads Revolution Medicines' $56M series B

Following its blueprint

Ideaya's focus on genomically defined subsets of cancer patients led oncology VC Nextech to co-lead its $94M series B round.

Revolution revamp

A strategic shift to cancer and preclinical POC data attracted Nextech to Revolution’s $56 million series B.

Future Farm Provides Details Regarding Nextech Spin-out

VANCOUVER, British Columbia, Sept. 6, 2018 /PRNewswire/ -- Future Farm Technologies Inc. (the "Company" or "Future Farm") (CSE: FFT) (OTCQX: FFRMF) would like to take Read more...

Arvinas closes $55mm Series C round

Arvinas Inc. (developing cancer therapeutics based on protein degradation) raised $55mm through its Series C round from new investors Nextech Invest (lead), Deerfield Management, Hillhouse Capital, an...

Revolution Medicines Raises Another $56 Million and Completes Pivot from Antifungal to Cancer Com...

Revolution Medicines closed on a Series B financing round worth $56 million. The round was led by Nextech Invest, with participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock V...

Revolution Medicines raises $56mm in Series B round

Cancer drug developer Revolution Medicines Inc. raised $56mm through its Series B round. Nextech Invest led (and takes a board seat) and was joined by Series A investors The Column Group and Third Roc...

Drugs and Medications [0 Results]

None

PubMed Articles [10 Associated PubMed Articles listed on BioPortfolio]

Grant Funding Needs Parallel the Start-Up Venture: An Analogy for Translational Research Success.

This editorial offers some ways to think about how best to position a research group for funding, by examining the parallels between what is needed for translational grants versus industry start-ups.

Skin Stem Cells in Silence, Action, and Cancer.

In studying how stem cells make and maintain tissues, nearly every chapter of a cell biology textbook takes on special interest. The field even allows us to venture where no chapters have yet been wri...

DKG Certification of Paediatric Cancer Centres.

The new certification module will continue to foster the development of interdisciplinary networks and a centralised commitment to high quality of care in paediatric oncology. The new module was initi...

Synthetic genomics: a new venture to dissect genome fundamentals and engineer new functions.

Since the first synthetic gene was synthesized in 1970s, the efficiency and the capacity of made-to-order DNA sequence synthesis has increased by several orders of magnitude. Advances in DNA synthesis...

Recent developments of microfluidics as a tool for biotechnology and microbiology.

Academic microfluidics has decisively shifted in recent years from the research on phenomenology and proof-of-concept fluidic functionalities to the developments oriented at applications with biology,...

Clinical Trials [6 Associated Clinical Trials listed on BioPortfolio]

Quest Sound Recover (SR2) vs. Venture SR2

Goal of this study is to determine the benefit of an improved feature on a new hearing aid platform. To investigate the improvements of this feature is compared on a new and older hearing...

Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Acute mountain sickness (AMS) is one of three syndromes of altitude illness. It is very common when people venture over 2500 meters altitude. This illness is mainly induced by acute exposu...

Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria

Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's Medicines and H...

Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria

CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a public-private partnership with the Medicines for Malaria Venture (MMV), World Health Organisation (WHO...

Promoting Healthier Food Purchases By Leveraging the Online-Grocery Environment

Rationale: Online-grocery shopping is predicted to be one of the "hottest" food trends of 2014, as national retailers such as Amazon, as well as start-up companies, venture into the e- com...

Companies [806 Associated Companies listed on BioPortfolio]

Nextech Venture, L.P

Nextech Venture, L.P., founded in 1999, is a U.S. limited partnership withCHF 70 million under management and with an office in Zurich, Switzerland. We are investing in selected life science companies...

Venture Cup Danmark

Venture Cup Denmark is a yearly held professional business plan competition. Teams must have at least one person related to a university or business school in Denmark [as a student at bachelor level,...

Stromedix, Inc.

Stromedix is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrotic organ failure. Investors in Stromedix include A...

Venture Valuation Inc.

Venture Valuation was founded in spring 1999 based on research work by the founder and CEO, Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne...

RiverVest Venture Management, LLC

RiverVest Venture Partners is a venture capital firm investing nationwide in emerging medical device, biopharmaceutical and other healthcare venture opportunities. With a total of more than 80 years o...

More Information about "Nextech Venture, L.P" on BioPortfolio

We have published hundreds of Nextech Venture, L.P news stories on BioPortfolio along with dozens of Nextech Venture, L.P Clinical Trials and PubMed Articles about Nextech Venture, L.P for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nextech Venture, L.P Companies in our database. You can also find out about relevant Nextech Venture, L.P Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record